Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MAPK Gene Mutation”

24 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 24 results

Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Testing effectiveness (Phase 2)Study completedNCT05039177
What this trial is testing

ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Who this might be right for
Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma
Erasca, Inc. 101
Not applicableAvailableNCT04566393
What this trial is testing

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Who this might be right for
Pancreatic CancerSmall Bowel CancerColorectal Cancer+18 more
xCures
Testing effectiveness (Phase 2)Ended earlyNCT04534283
What this trial is testing

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Who this might be right for
CancerCancer MetastaticBRAF V600E+4 more
Anita Turk 16
Large-scale testing (Phase 3)Active Not RecruitingNCT01933932
What this trial is testing

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Who this might be right for
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AstraZeneca 510
Testing effectiveness (Phase 2)WithdrawnNCT05279859
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Erasca, Inc.
Early research (Phase 1)Ended earlyNCT04249843
What this trial is testing

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Who this might be right for
Solid TumorB-Raf Mutation-Related Tumors
MapKure, LLC 109
Early research (Phase 1)Ended earlyNCT05375084
What this trial is testing

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Who this might be right for
Non Small Cell Lung CancerSolid Tumor
Navire Pharma Inc., a BridgeBio company 21
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Early research (Phase 1)Looking for participantsNCT06961565
What this trial is testing

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Who this might be right for
NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more
Pasithea Therapeutics Corp. 56
Testing effectiveness (Phase 2)Study completedNCT04735068
What this trial is testing

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerKRAS Mutation-Related Tumors
Abramson Cancer Center at Penn Medicine 9
Testing effectiveness (Phase 2)Ended earlyNCT04985604
What this trial is testing

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorCRAF Gene Amplification+20 more
Day One Biopharmaceuticals, Inc. 23
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Active Not RecruitingNCT05886920
What this trial is testing

D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd 67
Early research (Phase 1)Temporarily pausedNCT04418167
What this trial is testing

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Solid Tumors
JS InnoPharm, LLC 71
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Testing effectiveness (Phase 2)Study completedNCT05054374
What this trial is testing

Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Who this might be right for
Breast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 6
Early research (Phase 1)Ended earlyNCT05480865
What this trial is testing

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Who this might be right for
Solid Tumor, AdultMetastatic Solid TumorMetastatic NSCLC+1 more
Navire Pharma Inc., a BridgeBio company 28
Early research (Phase 1)Ended earlyNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 29
Load More Results